Clinical Trial Update: Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS [Phase 1]

View source ↗

Summary

Phase 1 trial of CFI-400945 fumarate in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CFI-400945 Fumarate (CFI-400945 fumarate)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED